Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 9Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 1Melanoma 1Glioblastoma 1Cholangiocarcinoma 1Advanced Gastrointestinal Stromal Tumor (GIST) 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Has results × infigratinib × Clear all
NCT04233567 2026-02-24

Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
17 enrolled 12 charts
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed
158 enrolled 40 charts
Dermatologic

Melanoma

NCT02257541 2020-03-30

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
16 enrolled 14 charts
GastrointestinalSarcoma

Advanced Gastrointestinal Stromal Tumor (GIST)

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Novartis

Phase 2 Completed
26 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡